Can matching drugs to tumor genes beat biliary cancer?
NCT ID NCT07729917
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This umbrella trial is testing whether assigning treatment based on a person's tumor genetics can improve outcomes for advanced biliary tract cancers. Participants receive one of several targeted therapies or immunotherapy, depending on their genetic test results. The study aims to see if this precision approach leads to tumor shrinkage and better survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of targeted drugs and immunotherapy matched to tumor genetics
- What this could lead to
- If successful, this approach could make treatment for biliary tract cancers more personalized and effective by matching drugs to each tumor's genetic makeup.
- What could go wrong
- This is an early-phase trial with many treatment arms, so results may not apply broadly. Some targeted drugs may cause side effects or not work for certain genetic profiles.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILE DUCT CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sound waves supercharge immunotherapy against bile duct cancer?
- A new test could reveal how radiation affects the liver
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
- Can freezing tumors boost immunotherapy in hard-to-treat bile duct cancers?